The new funds will help the personal genetics company launch new global user experience, grow its sales efforts and therapeutics discovery group efforts.
The Pathway Fit genetic test analyzes over 75 genetic markers known to impact metabolism, exercise, and energy consumption use within the human body.
The platform will enable next generation sequencing (NGS) researchers to share and cross-validate their tests/results against crowd-sourced reference material.
The company will use the funds to build its bioinformatics infrastructure, enhance sequencing facilities, and expand its research and scientific teams.
The two parties will explore the role of genetics and its influences in families experiencing unusual longevity using Ancestry's databases, tools and algorithms.
The first offering is a free service, that allows users to compile their family health history information with the help of their Ancestry family tree.
Toward the same goal, the company has recently hired Genentech veterans Robert Gentleman and Richard Scheller, who led drug discovery there.
The two parties will be working together to improve DNA analysis and help cure diseases through personalized healthcare based on an individual's DNA makeup.
Intermountain Healthcare, Healthbox and Tencent provided the capital, helping the company's efforts to enable genome-guided, individualized medicine.
The fresh capital will allow the company to accelerate into a beta commercial launch this fall; the money will also go towards enhancing the user experience.